ReviewPharmacoEconomics2018

Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal.

Xavier Armoiry et al.PubMed ↗Publisher ↗

No numbers read from the abstract.